Antibody drugs are usually generated
from monoclonal antibody through genetic engineering, with the advantages of
strong targeting, few side effects, etc. With rather promising application
prospect in clinic treatment, antibody drugs are mainly applied in curing
diseases like tumour, immune system and so on. In terms of the global market,
antibody drugs account for over 40% of the entire biotech drug market and the
market share still keeps increasing. Antibody drugs have become one of the most
important parts of biotech drugs and monoclonal antibody drugs are even star
products of antibody drugs. Among the top 10 best selling drugs in 2012, six of
them were monoclonal antibody drugs with each annual sales value exceeding USD
5 billion.
To
Read the Complete Report with TOC Visit:
http://www.marketresearchreports.biz/analysis-details/research-report-on-global-and-china-monoclonal-antibody-industry-2013-2017
In recent years, the market scale of
monoclonal antibody drugs increased rapidly. In 2012, the global sales value of
monoclonal antibody preparation exceeded USD 50 billion. Among that, Roche
(plus Genentech) was the leading monoclonal antibody enterprises, which
possessed seven products sold in the market including Avastin, Herceptin,
Rituximab, etc. In 2012, its sales value of monoclonal antibody products
reached USD 20 billion. Mono antibody drugs will become the main force
promoting the development of biological drugs in the next few years.
In recent years, China bio
pharmaceuticals industry develops rapidly, but antibody drugs lag far behind
the average international level with sales value being less than 3% of
biological drug share. At present, China antibody drug market is still in the
initial stage. However, with Shanghai CITIC National Health Pharmaceutical Co.,
Ltd. and Biotech Pharmaceutical Co., Ltd. releasing humanization products,
product types of domestic antibody drugs will enter the upgrading stage.
Although domestic full humanization products have not been released,
humanization products and full humanization products will become the domestic
trend of monoclonal antibody products in the future.
Contact
M/s Sheela
90 Sate Street, Suite
700
Albany, NY 12207
USA – Canada Toll
Free: 866-997-4948
No comments:
Post a Comment